Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Illumina
| Company | Illumina |
|---|---|
| Name of system | NextSeq 550Dx |
| City, State | San Diego, CA |
| Phone | 858-202-4500 |
| Website | |
| System application/FDA cleared or approved | in vitro diagnostic and research use/yes |
| Country where designed/Manufactured | U.S./Singapore |
| First year sold in U.S./First year installed in U.S. | 2017/2017 |
| System sold internationally | yes (Canada, Europe, Greater China, Asia Pacific, more) |
| Dimensions of sequencer (H × W × D)/Footprint of sequencer | — |
| Accessory equipment supplied with sequencer at no cost | — |
| Type of computer supplied with sequencer | computer for analysis and operations combined |
| Analysis options provided with sequencer | onboard, cloud based |
| Where library preparation is performed | accessory equipment, wet bench |
| Bioinformatics tools provided with sequencer | BaseSpace Sequence Hub, Local Run Manager, VeriSeq Onsite Server v2, VeriSeq Onsite Server upgraded to v2 |
| Sequencer supplied with UPS (uninterruptible power supply) | no |
| Electrical connection required for sequencer | 100–120 VAC at 50/60 Hz |
| List price of entire sequencer and necessary components | $347, 000 |
| Purchase options | purchase, trade in, lease, reagent rental |
| Warranties offered | first year included with purchase; extended warranty available |
| Training included/Total time for basic training per operator | yes/2 days |
| Training location/Follow-up training available | at customer site/yes (extra charge) |
| Maximum No. of samples amplified in a single amplification event | 384 samples (>384 samples with custom barcodes) |
| Read length/Percent bases >Q30 | up to 2 × 150 bp/75% |
| Paired-end capability/Tag lengths/Spans | yes/2 × 150 bp/up to 350 bp |
| Fragment/Tag lengths/Spans | yes/2 × 150 bp/up to 350 bp |
| Mate pair/Tag lengths/Spans | yes/2 × 150 bp/2–12 kb |
| Single end/Tag lengths/Spans | yes/up to 1 × 300 bp/up to 300 bp |
| RNA sequencing/Tag lengths/Spans | yes/up to 2 × 150 bp/up to 350 bp |
| ChIP sequencing/Tag lengths/Spans | yes/up to 2 × 150 bp/up to 350 bp |
| Bisulfite sequencing/Tag lengths/Spans | yes/up to 2 × 150 bp/up to 350 bp |
| Maximum No. of reads or fragments sequenced per single-end run | >300 million |
| Maximum No. of reads or fragments sequenced per paired-end run | >600 million |
| Total No. of nucleotides (bases) sequenced per run | up to 120 gb |
| Wet lab bench time for sequencing preparation | 10 minutes |
| Sequencing run time | <36 hours |
| Total time for generating standard gDNA library | <3.5 hours (with Illumina DNA Prep) |
| • Paired end | <3.5 hours (with Illumina DNA Prep) |
| • Fragment | <7 hours (with AmpliSeq for Illumina); <6.5 hours (with Illumina DNA Prep with Enrichment) |
| • Mate pair | — |
| • Single end | <4 hours (with TruSeq Small RNA) |
| • RNA sequencing | <3 hours |
| • Bisulfite sequencing | — |
| • Hands-on time for paired end | <1.5 hours (with Illumina DNA Prep) |
| • Hands-on time for fragment | <1.5 hours (with AmpliSeq for Illumina); <2 hours (with Illumina DNA Prep with Enrichment) |
| • Hands-on time for mate pair | — |
| • Hands-on time for single end | <4 hours (with TruSeq Small RNA) |
| • Hands-on time for RNA sequencing | <3 hours |
| • Hands-on time for ChIP sequencing | — |
| • Hands-on time for bisulfite sequencing | — |
| Library preparation integrated in system as standard offering | no |
| Cost of sequencing reagents per run | — |
| Reagent tracking method | RFID |
| • Type of reagent information tracked | serial No., expiration date, lot and part Nos., No. of cycles |
| Shipping conditions for amplification/sequencing reagents | — |
| Storage conditions for amplification/sequencing reagents | —/reagent cartridge, HT1 buffer: -15°– -25°C; flow cell: 2°–8°C; buffer cartridge: 15°–30°C |
| Shelf life of amplification/sequencing reagents | guaranteed 3 months/guaranteed 3 months |
| System requires a control sample on sequencing run | yes |
| • Company offers a sequencing control | yes (additional charge) |
| Sequencing system control software and devices to start run/for data analysis | NextSeq 550Dx Control Software and Operating Software/Local Run Manager, BaseSpace Sequence Hub |
| Complete walkaway automation for amplification, sequencing, and variant calling | yes |
| Remote system monitoring | yes |
| Total time required for setup of amplification, sequencing, and variant calling steps | 10 minutes |
| Maximum No. of libraries sequenced in a single run | 384 samples (>384 samples with custom barcodes) |
| System includes secondary data-analysis software developed by company | yes (BaseSpace Sequence Hub) |
| System includes post-sequencing data-analysis software | yes |
| Mutations detectable via data-analysis software | substitutions, indels, copy number changes |
| System can generate a variant report | yes |
| Types of maintenance plans available/mean time between failures | parts only, bronze, silver, gold, Dx, dedicated on-site/— |
| No. of field application scientists and engineers based in U.S. | >500 |
| • Weekly maintenance required | none (manual wash if instrument idle for 2 weeks) |
| • Monthly maintenance required | none |
| • Pre-run maintenance required | none (automatic wash completed after every run) |
| Distinguishing features of NGS system (supplied by company) | analyzes solid tumors using minimal tissue with TruSight Oncology Comprehensive, a reimbursable, validated, FDA-cleared test for in vitro diagnostics; runs IVD assays and laboratory-developed tests; 21 CFR part 11 compliant software |